The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IBC 2025 | Unmet needs and treatment opportunities for patients with MDS
Matteo Della Porta, MD, IRCCS Humanitas Research Hospital, Milan, Italy, highlights the differing unmet needs for patients with myelodysplastic syndromes (MDS) at various stages of the disease. Prof. Della Porter highlights that patients in earlier stages require treatments to improve anemia, while high-risk patients need therapies to delay leukemia transformation and improve survival. This interview took place at the 3rd Intercepting Blood Cancers (IBC) Workshop held in Nice, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that we have different needs associated with the different disease stages in MDS. In early disease stages, we know that severe transfusion-dependent anemia is the most relevant prognostic factor for all the patients. In this patient population, the unmet need is to try to improve anemia by using different kinds of drugs that should be implemented within clinical trials, while for high-risk patient populations, the unmet need is to try to delay the leukemia transformation and by this way to improve the patient’s survival...
I think that we have different needs associated with the different disease stages in MDS. In early disease stages, we know that severe transfusion-dependent anemia is the most relevant prognostic factor for all the patients. In this patient population, the unmet need is to try to improve anemia by using different kinds of drugs that should be implemented within clinical trials, while for high-risk patient populations, the unmet need is to try to delay the leukemia transformation and by this way to improve the patient’s survival. The treatment of high-risk patients with MDS is a challenge in clinical practice because we have only limited treatment opportunities. So I think that we have to perform innovative clinical trials, maybe in a subset of patients with homogeneous biological characteristics in order to check for innovative treatment opportunities.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
